Evaluating a Pivot: When Changing Direction Is Wisdom and When It's Denial
At some point in the life of most clinical-stage companies, management arrives at a board meeting with a new direction. The lead program has disappointed, or the market has shifted, or a competitor has arrived first, or the data have pointed somewhere the original plan did not anticipate — and the proposal is to pivot: to a new indication, a new endpoint, a new lead asset, a new therapeutic area, sometimes a substantially new company.
A pivot can be the smartest thing a company ever does. The history of biopharma is full of assets that found their value in an indication nobody originally targeted, and of teams whose willingness to abandon a failing plan for a better one is precisely what saved them. Rigidity in the face of disconfirming data destroys at least as many companies as flightiness does.
But a pivot can also be the most expensive form of denial available to a management team — a way of not admitting that the program has failed by relabeling failure as redirection, spending the last of the runway chasing a new story because the old one has run out. The board's central task when a pivot is proposed is to tell these two apart. And the tell, more often than not, is not in the quality of the new plan. It is in the honesty of the reckoning with the old one.
Why This Is Hard to Judge
The difficulty is that a good pivot and a denial pivot look remarkably similar from the outside, and they use the same vocabulary. Both are presented with conviction. Both come with a coherent-sounding rationale for why the new direction is promising. Both are advanced by a management team that genuinely believes in what it is proposing — because in the denial case, the team has usually convinced itself first. Self-deception precedes the pitch; the CEO proposing a denial pivot is very rarely being cynical.
The surface features that boards instinctively reach for do not reliably discriminate. The enthusiasm of the team tells you nothing — both kinds of pivot are pitched with energy. The internal coherence of the new plan tells you little — a plausible story can be constructed for almost any redirection, and the human mind is exceptionally good at building one when it needs to. Even the scientific rationale can be genuine in both cases; the question is never only whether the new direction could work but whether the company is turning to it for the right reasons and from an honest starting point.
Because the forward-looking features are unreliable, the board has to look backward. The most diagnostic information is not in the new plan at all. It is in how management accounts for what just happened.
The Reckoning With the Old Plan Is the Tell
The single most revealing question a board can ask when a pivot is proposed is not about the new direction. It is: why did the original plan fail, and what does that tell us about our ability to judge these things?
A healthy pivot rests on a clear, unflinching account of what went wrong. The team can say plainly: the original indication failed because of X, we now understand Y about the asset that we did not before, and the new direction is a response to that specific understanding. There is a genuine reckoning — an acknowledgment of what was misjudged, and ideally some evidence that the team has updated not just its plan but its thinking. The new direction follows logically from the lesson.
A denial pivot skips the reckoning. The failure of the original plan is minimized, reframed, or blamed entirely on external factors — the market, the regulator, the competitor, bad luck — with no acknowledgment of anything the team itself misjudged. The new direction is not derived from a lesson; it is a fresh story that happens to point away from the wreckage. When you ask "why did the last plan fail," you get defensiveness or deflection rather than analysis. This is the strongest single signal that the pivot is a flight from failure rather than a response to it. A team that cannot say clearly why the last thing failed has not learned anything that makes the next thing more likely to succeed.
So the board's first line of inquiry is backward-facing, and it should be pressed until it yields either a real answer or a revealing inability to give one. What specifically failed? Was it foreseeable? Did we see warning signs we rationalized at the time? What did we get wrong in our original judgment, as opposed to what the world did to us? A team that engages these questions seriously is a team the board can trust to have designed the new plan honestly. A team that resists them is telling the board something important about the plan it is about to propose.
Questions About the Pivot Itself
Once the backward-looking reckoning has been tested, the board turns to the proposed direction. Several questions matter.
Is this pivot driven by a positive signal or only by the absence of alternatives? There is a meaningful difference between "the data revealed an unexpected opportunity in this direction" and "the original plan failed and this is what's left." The first is a genuine redirection toward something promising. The second may still be reasonable — sometimes the remaining option really is the best available path — but the board should see it clearly for what it is, because a pivot justified only by the exhaustion of alternatives carries a very different risk profile than one justified by an affirmative finding.
What is the actual evidence for the new direction, and how does it compare to the evidence we had for the old one? A recurring pattern in denial pivots is that the new direction is supported by weaker evidence than the original plan was — often much weaker, sometimes little more than a hypothesis — yet is presented with equal or greater confidence. The board should explicitly compare the evidentiary basis of the new plan to what the company knew when it committed to the old one. If the company is pivoting from a well-characterized failed program to a thinly supported new one on the strength of enthusiasm, that asymmetry is a warning.
What does this pivot cost, and what does it consume? A pivot is rarely free. It often requires new capabilities, new trials, new time, and it consumes runway that is usually already constrained by the failure that prompted it. The board should force an honest accounting: how much runway does the pivot require, does the company have it, and if not, is the pivot actually a fundraising plan wearing the costume of a scientific plan? A pivot the company cannot afford to execute is not a strategy; it is a hope.
Are we keeping optionality, or betting everything again? Sometimes the right pivot preserves the ability to change course again if the new direction also disappoints. Sometimes it commits the last of the company's resources to a single new bet. The board should understand which it is, and be especially careful when a company that just bet everything and lost proposes to bet everything again on a less-proven thesis.
Is the team that misjudged the last plan the right team to execute the new one? This is uncomfortable and often necessary. Sometimes a pivot requires capabilities the current team does not have — a move into a new therapeutic area or modality where the team's expertise does not transfer. A board that approves the new direction without asking whether the company has the right people to pursue it has done half the job. This is not always a question about the CEO; more often it is about whether the organization's depth matches the new plan's demands.
The Traps
Several specific failure modes recur when boards evaluate pivots.
Approving the pivot to avoid admitting the failure. A board that backed the original plan has its own stake in not declaring it a failure. Approving a pivot can be a way for the board, not just management, to avoid a reckoning — to keep the story going rather than confront that the company's central thesis did not work. Directors should be honest with themselves about whether they are evaluating the pivot on its merits or reaching for it as a way to postpone a harder conversation about the company's viability.
Mistaking motion for progress. A pivot creates activity — new plans, new energy, a new narrative for investors — and activity can feel like progress even when it is flight. The board should be wary of the relief that a pivot brings to a demoralized situation, and should not let that relief substitute for judgment about whether the new direction is actually sound.
Serial pivoting. A company on its third or fourth pivot is usually telling the board something the individual pivots obscured: that the underlying asset or thesis does not work, and each redirection is a fresh rationalization rather than a genuine discovery. Each pivot may have looked defensible in isolation. The pattern is the finding. A board should track the history and treat a company that keeps changing direction as a company that may need to confront a more fundamental question than "where do we point next."
Letting the sunk cost of the old plan justify the new one. "We've invested so much, we can't just stop" is an argument for a pivot that has nothing to do with the pivot's merits. The resources already spent on the failed plan are gone regardless of what the company does next. The only question is whether the new direction is worth the resources it will consume from here — and the answer to that does not depend in any way on what was spent before.
When the Right Answer Is Not to Pivot
It is worth stating plainly, because boards under the emotional pressure of a failed program can forget it: sometimes the right response to a failure is not a pivot at all. Sometimes it is to return capital to shareholders, to wind the program down and preserve resources for a genuinely separate opportunity, or to seek a transaction while the company still has assets worth something. A pivot is one option among several, not the default response to disappointment.
A board that treats every failure as a prompt to find a new direction has quietly decided that the company must continue regardless of whether continuing serves anyone. The most disciplined boards keep "should we continue at all" on the table alongside "where should we go next," and are willing to conclude, when the honest reckoning points that way, that the best pivot is no pivot — that the responsible course is to stop, and to steward what remains rather than spend it chasing a fresh story.
The Underlying Principle
Evaluating a pivot is one of the purest tests of a board's independence, because the pressure — internal and often self-generated — runs so strongly toward approval. The proposal comes wrapped in conviction, coherence, and the relief of a way forward, and all three are present whether the pivot is wisdom or denial.
The discipline that separates them is to look backward before looking forward: to insist on an honest, specific reckoning with why the last plan failed, and to treat the quality of that reckoning as the leading indicator of whether the new plan was built on a lesson or on a wish. A team that can tell you clearly and without defensiveness why it was wrong before has earned a serious hearing for what it proposes to do next. A team that cannot has told the board most of what it needs to know.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.